STAT3 and melanoma: As Lrg1-/- mice are healthy and have a normal life span, unlike mice treated with current STAT3 inhibitors, targeting LRG1 may cause fewer unwanted side effects and offers an alternative strategy to control STAT3-mediated melanoma metastasis.